Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Analyst consensus.
ACCE opinionRoivant Sciences Ltd. Common Shares (ROIV)
Fair value
Not available
ACCE price target
$32.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 18 Oct 2026, 01:52 CEST; previously $40.00 since 24 Sept 2026, 00:00 CEST.
Price used: $36.49 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
41
out of 100
Analysts
85% buy
13 covering
P/E
0.0x
forward 0.0x
1-year return
+101.4%
Dividend yield
0.00%
Roivant Sciences Ltd. Common Shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Roivant Sciences is a holding company that develops and commercializes drugs through subsidiaries, with its most prominent asset being the Vtama topical treatment for atopic dermatitis, alongside programs in immunology, neurology and rare disease. The investment case rests on the platform model: Roivant sources drug candidates that are often out-licensed or spun into partially owned subsidiaries, so value depends on pipeline readouts and partnering milestones rather than on a single commercial franchise. Revenue fell 33.5% year over year and the operating margin is deeply negative at -25,408%, reflecting how little product revenue exists against a large development and R&D cost base. Against a $25.0B market cap, the valuation therefore rests almost entirely on pipeline optionality, with no meaningful earnings to anchor it. Our composite score of 41/100 and the absence of index membership suggest this name warrants a deeper look only if the pipeline and milestone timing can be underwritten independently of the current financials.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
severe
Massive negative margins
Gross margin -9610.9%, operating margin -25408.1%. Company is burning cash at unsustainable rate with no path to profitability visible in current data.
severe
Revenue collapse and FCF burn
Revenue down 33.5% YoY and 42.8% QoQ. Negative FCF of $758.6M annually. Cash runway is critical concern for biotech with no approved products generating revenue.
high
Insider selling without buying
Last 10 disclosures show $113.14M in insider sales and $0 in buys. Heavy selling by insiders during period of deteriorating fundamentals signals lack of confidence.
high
Earnings collapse
Earnings down 96.1% YoY. Combined with negative margins and revenue decline, suggests pipeline failures or major setbacks in clinical development.
AI research notes
AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Analyst consensus sees 35.7% upside to $48.08, with 92% of analysts rating the stock Buy or Strong Buy.
Management reduced share count by 4.3% last fiscal year, offsetting dilution and concentrating value per share.
Balance sheet is fortress-like with debt to equity of only 0.02, providing flexibility to fund pipeline development.
Why it could disappoint
Revenue fell 33.5% year over year and has declined 19.1% annually over five years, showing persistent contraction.
Free cash flow of negative $759M over the last 12 months means the company burns cash faster than it generates it.
Net margin of 0.0% and negative ROE of negative 8.5% show the company is not generating profits or returns on shareholder capital.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 9, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where ROIV's valuation models land
Price
$36.49
Model fair valueConfidence: low
about $48.27
Model
Fair value
Upside
Analyst consensus
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores